{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:18Z","timestamp":1792417398461,"version":"4.4.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.4103\/aian.aian_889_25","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:00:10Z","timestamp":1769144410000},"page":"296-297","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dasatinib: A Novel Etiology of Reversible Cerebellar Ataxia"],"prefix":"10.4103","volume":"29","author":[{"given":"Farsana","family":"Mustafa","sequence":"first","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyani","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achal K","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"R1-20261019","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: A review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/aian.aian_841_24","article-title":"Isolated central and peripheral nervous system relapse in chronic myeloid leukemia: A report of two cases with review of literature","volume":"28","author":"Mustafa","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5045\/br.2023.2023057","article-title":"Atypical posterior reversible encephalopathy syndrome secondary to dasatinib","volume":"58","author":"Nayak","year":"2023","journal-title":"Blood Res"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.htct.2019.01.003","article-title":"A case of neurocognitive deficit strongly related to dasatinib therapy","volume":"42","author":"Chamoun","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.2147\/DDDT.S521260","article-title":"Dasatinib dose optimization based on therapeutic drug monitoring in patients with chronic-phase chronic myeloid leukemia","volume":"19","author":"Cheng","year":"2025","journal-title":"Drug Des Devel Ther"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_889_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:02:17Z","timestamp":1792414937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_889_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_889_25","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-08-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}